Natco Pharma Limited - Asset Resilience Ratio
Natco Pharma Limited (NATCOPHARM) has an Asset Resilience Ratio of 63.89% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Natco Pharma Limited's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Natco Pharma Limited to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Natco Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NATCOPHARM company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs26.90 Billion | 25.79% |
| Short-term Investments | Rs39.73 Billion | 38.09% |
| Total Liquid Assets | Rs66.64 Billion | 63.89% |
Asset Resilience Insights
- Very High Liquidity: Natco Pharma Limited maintains exceptional liquid asset reserves at 63.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Natco Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Natco Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Natco Pharma Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Natco Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 31.76% | Rs27.41 Billion ≈ $296.48 Million |
Rs86.31 Billion ≈ $933.39 Million |
+6.95pp |
| 2024-03-31 | 24.82% | Rs17.14 Billion ≈ $185.36 Million |
Rs69.06 Billion ≈ $746.89 Million |
-0.06pp |
| 2023-03-31 | 24.88% | Rs14.07 Billion ≈ $152.19 Million |
Rs56.57 Billion ≈ $611.83 Million |
+12.18pp |
| 2022-03-31 | 12.70% | Rs6.49 Billion ≈ $70.17 Million |
Rs51.09 Billion ≈ $552.53 Million |
-3.83pp |
| 2021-03-31 | 16.53% | Rs7.92 Billion ≈ $85.64 Million |
Rs47.92 Billion ≈ $518.23 Million |
-2.71pp |
| 2020-03-31 | 19.24% | Rs8.83 Billion ≈ $95.46 Million |
Rs45.88 Billion ≈ $496.15 Million |
-4.68pp |
| 2019-03-31 | 23.92% | Rs10.29 Billion ≈ $111.31 Million |
Rs43.03 Billion ≈ $465.36 Million |
+1.72pp |
| 2018-03-31 | 22.20% | Rs8.25 Billion ≈ $89.18 Million |
Rs37.15 Billion ≈ $401.77 Million |
+17.29pp |
| 2017-03-31 | 4.91% | Rs1.14 Billion ≈ $12.30 Million |
Rs23.18 Billion ≈ $250.64 Million |
+3.76pp |
| 2016-03-31 | 1.15% | Rs209.64 Million ≈ $2.27 Million |
Rs18.24 Billion ≈ $197.24 Million |
+1.14pp |
| 2015-03-31 | 0.01% | Rs1.18 Million ≈ $12.79K |
Rs13.84 Billion ≈ $149.68 Million |
-0.02pp |
| 2014-03-31 | 0.03% | Rs3.18 Million ≈ $34.39K |
Rs11.96 Billion ≈ $129.31 Million |
-0.05pp |
| 2013-03-31 | 0.08% | Rs8.12 Million ≈ $87.83K |
Rs10.80 Billion ≈ $116.84 Million |
-0.01pp |
| 2012-03-31 | 0.08% | Rs7.37 Million ≈ $79.76K |
Rs9.03 Billion ≈ $97.63 Million |
-9.70pp |
| 2011-03-31 | 9.78% | Rs691.96 Million ≈ $7.48 Million |
Rs7.07 Billion ≈ $76.49 Million |
+1.43pp |
| 2010-03-31 | 8.36% | Rs460.41 Million ≈ $4.98 Million |
Rs5.51 Billion ≈ $59.58 Million |
-8.29pp |
| 2009-03-31 | 16.65% | Rs859.93 Million ≈ $9.30 Million |
Rs5.17 Billion ≈ $55.86 Million |
+2.77pp |
| 2008-03-31 | 13.88% | Rs581.93 Million ≈ $6.29 Million |
Rs4.19 Billion ≈ $45.36 Million |
-2.82pp |
| 2007-03-31 | 16.69% | Rs583.87 Million ≈ $6.31 Million |
Rs3.50 Billion ≈ $37.83 Million |
+2.74pp |
| 2006-03-31 | 13.95% | Rs429.69 Million ≈ $4.65 Million |
Rs3.08 Billion ≈ $33.30 Million |
-1.36pp |
| 2005-03-31 | 15.31% | Rs439.99 Million ≈ $4.76 Million |
Rs2.87 Billion ≈ $31.08 Million |
-- |
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more